Literature DB >> 34866787

Imeglimin.

Megan Giruzzi1.   

Abstract

Entities:  

Year:  2021        PMID： 34866787      PMCID： PMC8603315          DOI： 10.2337/cd21-0085

Source DB:  PubMed          Journal:  Clin Diabetes        ISSN： 0891-8929


× No keyword cloud information.
  6 in total

1.  Efficacy and Safety of Imeglimin Monotherapy Versus Placebo in Japanese Patients With Type 2 Diabetes (TIMES 1): A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Phase 3 Trial.

Authors:  Julie Dubourg; Pascale Fouqueray; Carole Thang; Jean-Marie Grouin; Kohjiro Ueki
Journal:  Diabetes Care       Date:  2021-02-11       Impact factor: 19.112

2.  Imeglimin, a novel glimin oral antidiabetic, exhibits a good efficacy and safety profile in type 2 diabetic patients.

Authors:  V Pirags; H Lebovitz; P Fouqueray
Journal:  Diabetes Obes Metab       Date:  2012-05-16       Impact factor: 6.577

3.  The efficacy and safety of imeglimin as add-on therapy in patients with type 2 diabetes inadequately controlled with sitagliptin monotherapy.

Authors:  Pascale Fouqueray; Valdis Pirags; Michaela Diamant; Guntram Schernthaner; Harold E Lebovitz; Silvio E Inzucchi; Clifford J Bailey
Journal:  Diabetes Care       Date:  2014-04-10       Impact factor: 19.112

4.  The efficacy and safety of imeglimin as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy.

Authors:  Pascale Fouqueray; Valdis Pirags; Silvio E Inzucchi; Clifford J Bailey; Guntram Schernthaner; Michaela Diamant; Harold E Lebovitz
Journal:  Diabetes Care       Date:  2012-11-16       Impact factor: 19.112

5.  Efficacy and safety of imeglimin in Japanese patients with type 2 diabetes: A 24-week, randomized, double-blind, placebo-controlled, dose-ranging phase 2b trial.

Authors:  Julie Dubourg; Kohjiro Ueki; Jean-Marie Grouin; Pascale Fouqueray
Journal:  Diabetes Obes Metab       Date:  2021-01-13       Impact factor: 6.577

Review 6.  Mechanism of action of Imeglimin: A novel therapeutic agent for type 2 diabetes.

Authors:  Sophie Hallakou-Bozec; Guillaume Vial; Micheline Kergoat; Pascale Fouqueray; Sébastien Bolze; Anne-Laure Borel; Eric Fontaine; David E Moller
Journal:  Diabetes Obes Metab       Date:  2020-12-29       Impact factor: 6.577
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.